Carol Wysham is an Endocrinology/Metabolic physician affiliated with Rockwood Clinic. OpenAlex indexes 123 publications with 4,827 citations (h-index 28).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
400 E 5th Ave
Spokane, WA 992021334
Telephone
509-838-2531Registry record last updated 15 Dec 2008.
Industry payments
16 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Abbott LaboratoriesProgram year202590 payments$48,486openpaymentsdata.cms.gov ↗
- Novo Nordisk IncProgram year202532 payments$46,859openpaymentsdata.cms.gov ↗
- Eli Lilly and CompanyProgram year202514 payments$21,928openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Musculoskeletal
55.4%RANK Ligand Inhibitor55%Denosumab100%Part B, office-administered≥39 patientsOther drugs affecting bone structure and mineralization0.2%Crysvita100%Part D<11 patients+ 1 more class in this area
Metabolism & gastrointestinal
17.4%Insulin Analog5.7%Lantus Solostar17%Novolog Flexpen13%Tresiba Flextouch U-10011%Humalog Kwikpen U-1009%Insulin Lispro7%Humalog7%Fiasp Flextouch6%Basaglar Kwikpen U-1006%Novolog6%Novolog Penfill5%Insulin Lispro Kwikpen U-1004%Toujeo Solostar4%Toujeo Max Solostar3%Humalog Kwikpen U-2003%Part D<11 patientsBiguanide (metformin)3.4%Metformin Hcl Er63%Metformin Hcl37%Part D≥49 patients+ 9 more classes in this area
Cardiovascular
13.8%Statin6.3%Rosuvastatin Calcium60%Atorvastatin Calcium30%Pravastatin Sodium8%Simvastatin3%Part D<11 patientsCholesterol absorption inhibitor1.9%Ezetimibe100%Part D≥47 patients+ 8 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- A systematic literature review on the burden of diabetic ketoacidosis in type 2 diabetes mellitus
Diabetes Obesity and Metabolism
2025 - Insulin Efsitora versus Degludec in Type 2 Diabetes without Previous Insulin Treatment
New England Journal of Medicine
2024 - Once‐weekly insulin efsitora alfa: Design and rationale for the QWINT phase 3 clinical development programme
Diabetes Obesity and Metabolism
2024 - Tirzepatide for the treatment of adults with type 2 diabetes: An endocrine perspective
Diabetes Obesity and Metabolism
2022
Similar KOLs
Other experts from the same institution or the same specialty.
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”